This regulatory mechanism unveils novel therapeutic avenues for hemoglobinopathies: Inhibiting TR2/TR4 activity or targeting their binding sites can reactivate HbF, alleviating erythroid pathological phenotypes in SCD [71,122]. The gene discussed is NR2C2; the disease is hemoglobinopathy.